(NBIX) Neurocrine Biosciences - Overview

Sector: Healthcare | Industry: Drug Manufacturers - Specialty & Generic | Exchange: NASDAQ (USA) | Market Cap: 16.141m USD | Total Return: 31.7% in 12m

Movement Disorder Drugs, Endocrine Treatments, Neuropsychiatric Medicines
Total Rating 78
Safety 86
Buy Signal 0.68
Drug Manufacturers - Specialty & Generic
Industry Rotation: -1.3
Market Cap: 16.1B
Avg Turnover: 192M
Risk 3d forecast
Volatility31.9%
VaR 5th Pctl4.92%
VaR vs Median-7.79%
Reward TTM
Sharpe Ratio0.93
Rel. Str. IBD72.9
Rel. Str. Peer Group41.8
Character TTM
Beta0.528
Beta Downside0.287
Hurst Exponent0.500
Drawdowns 3y
Max DD42.89%
CAGR/Max DD0.45
CAGR/Mean DD1.87
EPS (Earnings per Share) EPS (Earnings per Share) of NBIX over the last years for every Quarter: "2021-03": 0.33, "2021-06": 0.43, "2021-09": 0.64, "2021-12": -0.08, "2022-03": 0.14, "2022-06": -0.18, "2022-09": 0.69, "2022-12": 0.88, "2023-03": -0.79, "2023-06": 0.95, "2023-09": 0.82, "2023-12": 1.44, "2024-03": 0.42, "2024-06": 0.63, "2024-09": 1.81, "2024-12": 1.69, "2025-03": 0.7, "2025-06": 1.65, "2025-09": 2.17, "2025-12": 1.88, "2026-03": 1.94,
EPS CAGR: 44.94%
EPS Trend: 70.3%
Last SUE: 3.05
Qual. Beats: 1
Revenue Revenue of NBIX over the last years for every Quarter: 2021-03: 236.6, 2021-06: 288.9, 2021-09: 296, 2021-12: 312, 2022-03: 310.6, 2022-06: 378.2, 2022-09: 387.9, 2022-12: 412, 2023-03: 420.4, 2023-06: 452.7, 2023-09: 498.8, 2023-12: 515.2, 2024-03: 515.3, 2024-06: 590.2, 2024-09: 622.1, 2024-12: 627.7, 2025-03: 572.6, 2025-06: 687.5, 2025-09: 794.9, 2025-12: 805.5, 2026-03: 814.5,
Rev. CAGR: 22.70%
Rev. Trend: 98.2%
Last SUE: 2.51
Qual. Beats: 1

Warnings

No concerns identified

Tailwinds

Confidence

Description: NBIX Neurocrine Biosciences

Neurocrine Biosciences, Inc. (NBIX) is a biopharmaceutical company focused on the development and commercialization of treatments for neurological, endocrine, and psychiatric disorders. Its primary revenue driver is INGREZZA, used for tardive dyskinesia and Huntingtons disease chorea, complemented by a portfolio addressing endometriosis and uterine fibroids. The company maintains a high-volume clinical pipeline with active candidates targeting schizophrenia, Alzheimer’s disease, and major depressive disorder.

Operating within the biotechnology sector, the company utilizes a research-intensive business model characterized by high research and development (R&D) expenditure and strategic licensing agreements. By collaborating with established global firms like Takeda and AbbVie, Neurocrine mitigates the capital risks associated with late-stage clinical trials and international distribution. Investors should monitor the companys patent lifecycle and regulatory milestones to gauge long-term valuation.

For a deeper dive into these financial metrics and valuation trends, consider reviewing the latest data on ValueRay.

Headlines to Watch Out For
  • Ingrezza market penetration and prescription volume drive primary quarterly revenue growth
  • Crinecerfont FDA approval and commercial launch timing impact long-term valuation
  • Clinical trial data for schizophrenia candidate NBI-1117568 determines future pipeline viability
  • Expansion of Ingrezza label to include Huntington’s chorea captures new market share
  • High R&D expenditure on neuropsychiatric pipeline assets pressures near-term operating margins
Piotroski VR‑10 (Strict) 6.0
Net Income: 668.6m TTM > 0 and > 6% of Revenue
FCF/TA: 0.17 > 0.02 and ΔFCF/TA 3.60 > 1.0
NWC/Revenue: 51.71% < 20% (prev 46.22%; Δ 5.50% < -1%)
CFO/TA 0.18 > 3% & CFO 863.7m > Net Income 668.6m
Net Debt (-910.0m) to EBITDA (881.2m): -1.03 < 3
Current Ratio: 2.93 > 1.5 & < 3
Outstanding Shares: last quarter (103.4m) vs 12m ago 0.88% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 72.20% > 50% (prev 65.42%; Δ 6.78% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' 4.28
A: 0.33 (Total Current Assets 2.44b - Total Current Liabilities 831.7m) / Total Assets 4.91b
B: 0.12 (Retained Earnings 589.6m / Total Assets 4.91b)
C: 0.20 (EBIT TTM 851.4m / Avg Total Assets 4.30b)
D: 0.39 (Book Value of Equity 590.1m / Total Liabilities 1.50b)
Altman-Z'' Score: 4.28 = AA
Beneish M -2.73
DSRI: 1.16 (Receivables 768.1m/516.0m, Revenue 3.10b/2.41b)
GMI: 1.00 (GM 98.17% / 98.52%)
AQI: 0.99 (AQ_t 0.39 / AQ_t-1 0.40)
SGI: 1.29 (Revenue 3.10b / 2.41b)
TATA: -0.04 (NI 668.6m - CFO 863.7m) / TA 4.91b)
Beneish M-Score: -2.73 (Cap -4..+1) = A
What is the price of NBIX shares? As of May 17, 2026, the stock is trading at USD 158.42 with a total of 1,307,347 shares traded.
Over the past week, the price has changed by +4.05%, over one month by +20.53%, over three months by +24.00% and over the past year by +31.72%.
Is NBIX a buy, sell or hold? Neurocrine Biosciences has received a consensus analysts rating of 4.48. Therefore, it is recommended to buy NBIX.
  • StrongBuy: 15
  • Buy: 7
  • Hold: 3
  • Sell: 0
  • StrongSell: 0
What are the forecasts/targets for the NBIX price?
Analysts Target Price 191 20.6%
Neurocrine Biosciences (NBIX) - Fundamental Data Overview as of 14 May 2026
P/E Trailing = 24.6962
P/E Forward = 21.5983
P/S = 4.8807
P/B = 4.4928
P/EG = 0.4322
Revenue TTM = 3.10b USD
EBIT TTM = 851.4m USD
EBITDA TTM = 881.2m USD
Long Term Debt = 406.2m USD (from capitalLeaseObligations, last quarter)
 Short Term Debt = unknown (none)
 Debt = 406.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -910.0m USD (recalculated: Debt 406.2m - CCE 1.32b)
Enterprise Value = 15.23b USD (16.14b + Debt 406.2m - CCE 1.32b)
 Interest Coverage Ratio = unknown (Ebit TTM 851.4m / Interest Expense TTM 0.0)
 EV/FCF = 18.32x (Enterprise Value 15.23b / FCF TTM 831.3m)
FCF Yield = 5.46% (FCF TTM 831.3m / Enterprise Value 15.23b)
FCF Margin = 26.80% (FCF TTM 831.3m / Revenue TTM 3.10b)
Net Margin = 21.55% (Net Income TTM 668.6m / Revenue TTM 3.10b)
 Gross Margin = unknown ((Revenue TTM 3.10b - Cost of Revenue TTM 56.7m) / Revenue TTM)
 Tobins Q-Ratio = 3.10 (Enterprise Value 15.23b / Total Assets 4.91b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 406.2m)
Taxrate = 19.81% (48.9m / 246.8m)
NOPAT = 682.7m (EBIT 851.4m * (1 - 19.81%))
Current Ratio = 2.93 (Total Current Assets 2.44b / Total Current Liabilities 831.7m)
Debt / Equity = 0.12 (Debt 406.2m / totalStockholderEquity, last quarter 3.41b)
Debt / EBITDA = -1.03 (Net Debt -910.0m / EBITDA 881.2m)
Debt / FCF = -1.09 (Net Debt -910.0m / FCF TTM 831.3m)
Total Stockholder Equity = 3.09b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.56% (Net Income 668.6m / Total Assets 4.91b)
RoE = 21.64% (Net Income TTM 668.6m / Total Stockholder Equity 3.09b)
RoCE = 24.35% (EBIT 851.4m / Capital Employed (Equity 3.09b + L.T.Debt 406.2m))
RoIC = 22.10% (NOPAT 682.7m / Invested Capital 3.09b)
WACC = 7.65% (E(16.14b)/V(16.55b) * Re(7.84%) + D(406.2m)/V(16.55b) * Rd(0.0%) * (1-Tc(0.20)))
Discount Rate = 7.84% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.92%
Shares (quarterly) Correlation: -13.80 | Cagr: 0.48%
[DCF] Terminal Value 82.75% ; FCFF base≈695.7m ; Y1≈858.2m ; Y5≈1.46b
[DCF] Fair Price = 278.9 (EV 27.13b - Net Debt -910.0m = Equity 28.04b / Shares 100.5m; r=7.65% [WACC]; 5y FCF grow 25.0% → 3.0% )
EPS Correlation: 70.28 | EPS CAGR: 44.94% | SUE: 3.05 | # QB: 1
Revenue Correlation: 98.22 | Revenue CAGR: 22.70% | SUE: 2.51 | # QB: 1
EPS current Quarter (2026-06-30): EPS=2.11 | Chg30d=+9.95% | Revisions=+53% | Analysts=14
EPS next Quarter (2026-09-30): EPS=3.37 | Chg30d=+58.73% | Revisions=+43% | Analysts=11
EPS current Year (2026-12-31): EPS=10.27 | Chg30d=+33.77% | Revisions=+56% | GrowthEPS=+60.6% | GrowthRev=+31.5%
EPS next Year (2027-12-31): EPS=12.71 | Chg30d=+48.59% | Revisions=+50% | GrowthEPS=+23.8% | GrowthRev=+19.7%
[Analyst] Revisions Ratio: +56%